Scarica l'app Stockscreener
193.76
2.26%
4.29
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$189.47
Aprire:
$190.53
Volume 24 ore:
892.90K
Relative Volume:
0.79
Capitalizzazione di mercato:
$28.61B
Reddito:
$9.60B
Utile/perdita netta:
$1.37B
Rapporto P/E:
20.79
EPS:
9.3182
Flusso di cassa netto:
$2.32B
1 W Prestazione:
+0.42%
1M Prestazione:
+1.94%
6M Prestazione:
+10.53%
1 anno Prestazione:
+53.41%
Intervallo 1D:
$190.00
$194.75
Intervallo di 1 settimana:
$185.85
$194.75
Portata 52W:
$121.05
$205.97
Biogen Inc Stock (BIIB) Company Profile
Nome
Biogen Inc
Settore
Industria
Telefono
(781) 464-2000
Indirizzo
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, MRK, AZN
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
193.76 | 27.97B | 9.60B | 1.37B | 2.32B | 9.3182 |
LLY
Lilly Eli Co
|
1,065.00 | 928.88B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
234.34 | 557.82B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
215.70 | 378.98B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
122.41 | 286.20B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
187.03 | 294.27B | 60.48B | 10.40B | 8.05B | 3.3297 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-22 | Aggiornamento | UBS | Neutral → Buy |
| 2026-04-20 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2026-04-14 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2026-02-20 | Iniziato | Barclays | Equal Weight |
| 2026-02-09 | Reiterato | H.C. Wainwright | Buy |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-10 | Downgrade | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Aggiornamento | Stifel | Hold → Buy |
| 2025-09-25 | Iniziato | Jefferies | Buy |
| 2025-07-21 | Ripresa | Truist | Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-04-04 | Downgrade | Argus | Buy → Hold |
| 2025-02-11 | Iniziato | Bernstein | Mkt Perform |
| 2025-01-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Downgrade | Stifel | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-09 | Downgrade | Jefferies | Buy → Hold |
| 2024-11-18 | Downgrade | Needham | Buy → Hold |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-10-31 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-02-14 | Reiterato | Needham | Buy |
| 2024-02-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2023-12-20 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-07-24 | Reiterato | UBS | Buy |
| 2023-05-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-04-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-10-13 | Aggiornamento | Stifel | Hold → Buy |
| 2022-10-07 | Aggiornamento | Argus | Hold → Buy |
| 2022-09-28 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Aggiornamento | Mizuho | Neutral → Buy |
| 2022-09-28 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Downgrade | Stifel | Buy → Hold |
| 2022-03-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Reiterato | Barclays | Equal Weight |
| 2022-02-04 | Reiterato | BofA Securities | Neutral |
| 2022-02-04 | Reiterato | Cowen | Outperform |
| 2022-02-04 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-04 | Reiterato | Needham | Buy |
| 2022-02-04 | Reiterato | Oppenheimer | Outperform |
| 2022-02-04 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Reiterato | Robert W. Baird | Neutral |
| 2022-02-04 | Reiterato | Wedbush | Neutral |
| 2022-02-04 | Reiterato | Wells Fargo | Equal Weight |
| 2022-02-04 | Reiterato | Wolfe Research | Peer Perform |
| 2022-01-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-01-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Ripresa | Raymond James | Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-06-18 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Reiterato | Truist | Buy |
| 2021-06-11 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-08 | Aggiornamento | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Reiterato | Barclays | Equal Weight |
| 2021-06-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-06-08 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-08 | Reiterato | Jefferies | Buy |
| 2021-06-08 | Reiterato | Morgan Stanley | Overweight |
| 2021-06-08 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Reiterato | Stifel | Buy |
| 2021-06-08 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-06-07 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Downgrade | DZ Bank | Buy → Hold |
| 2021-01-29 | Aggiornamento | Stifel | Hold → Buy |
| 2020-11-10 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-11-09 | Downgrade | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-11-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-04 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-11-04 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-07-27 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Downgrade | Citigroup | Neutral → Sell |
| 2020-04-23 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-01-27 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Downgrade | Robert W. Baird | Neutral → Underperform |
Mostra tutto
Biogen Inc Borsa (BIIB) Ultime notizie
Biogen Inc. (NASDAQ: BIIB) Navigates Alzheimer’s Drug Trajectory After Leqembi Updates - foreignpolicyjournal.com
Biogen Faces Trial Setbacks And Probes That Reframe Neuro Pipeline Risks - Yahoo Finance UK
Biogen and Denali Halt Development of BIIB122 After Phase 2b LUMA Study Fails in Early Parkinson’s Disease - Minichart
Parkinson’s drug from Biogen, Denali comes up short - BioPharma Dive
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails - Yahoo Finance
Biogen Inc. (BIIB) Securities Fraud InvestigationLevi & Korsinsky - PR Newswire
Biogen (BIIB) and Denali (DNLI) Halt Development of BIIB122 Afte - GuruFocus
Biogen Stock Slides After Trial Miss, but Analysts Stay Bullish - Investing.com
Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish - MarketBeat
Biogen, Denali pull plug on Parkinson’s program after mid-stage flop - BioSpace
Biogen, Denali to drop Parkinson’s therapy (BIIB:NASDAQ) - Seeking Alpha
Denali Therapeutics and Biogen discontinue BIIB122 after Phase 2b LUMA misses endpoints - TradingView
Biogen, Denali scrap Parkinson’s candidate after Phase IIb miss - The Pharma Letter
Biogen, Denali axe LRRK2 inhibitor in idiopathic Parkinson’s after mid-stage miss - FirstWord Pharma
Biogen stock (US09062X1037): Parkinson’s drug setback hits pipeline - AD HOC NEWS
Parkinson’s trial setback: Biogen, Denali halt BIIB122 program, await 2027 data - Stock Titan
Biogen and Denali Therapeutics Halt BIIB122 Development After Tr - GuruFocus
Biogen and Denali halt BIIB122 development after Phase 2b Parkinson's study fails to meet endpoints - Pluang
BIIB, DNLI Stocks Edge Lower After Hours: Parkinson’s Drug Misses Key Goals In Trial - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc.BIIB - PR Newswire
Biogen, Denali scrap Parkinson’s drug after failure in mid-to-late stage study - WNWN-FM
Biogen (BIIB) Halts Development of BIIB122 After Phase 2b Study Results - GuruFocus
Biogen, Denali discontinue Parkinson’s drug after trial fails By Investing.com - Investing.com Australia
[8-K] Denali Therapeutics Inc. Reports Material Event - Stock Titan
Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study - Reuters
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease - Biogen
Biogen Patent Suit Targets Somerset’s Copy of Spinraza Therapy - Bloomberg Law News
Apellis soars on Biogen deal as biopharma index trails the market - BioWorld News
(BIIB) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Biogen stock (US09062X1037): FDA decision keeps investors focused - AD HOC NEWS
Biogen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Apellis Shares Disappear After Biogen’s $5.6 Billion Buy—One Play Left - TechStock²
Levi & Korsinsky Announces Investigation of Securities Claims Against Biogen Inc. (BIIB) - GlobeNewswire
Are Wall Street Analysts Bullish on Biogen Stock? - Yahoo Finance
How Biogen’s Diranersen Alzheimer’s Bet Will Impact Biogen (BIIB) Investors - simplywall.st
Ionis Rises As Diranersen Phase 2 Spurs Biogen Registrational Plans - simplywall.st
Biogen stock (US09062X1037): Alzheimer data and Q1 earnings keep focus on biotech transition - AD HOC NEWS
Biogen Earnings Call Signals Confident, Investment-Heavy Transition - TipRanks
BIIB Investor Alert: Levi & Korsinsky Investigates Biogen Inc. (BIIB) for Potential Securities Fraud - Business Wire
Biogen Inc (BIIB) Stock Price, Trades & News - GuruFocus
Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout - Proactive financial news
Biogen stock (US09062X1037): Alzheimer’s focus after Leqembi setback and pipeline updates - AD HOC NEWS
Biogen Inc. stock underperforms Thursday when compared to competitors - MSN
Biogen’s Apellis Deal And Alzheimer’s Trial Shift Focus Beyond Price - Yahoo Finance
Investigation launched into Biogen after Alzheimer's drug trial misses key goal, stock drops sharply. - Pluang
Biogen shares drop 6.4% after Phase 2 trial misses primary endpoint for diranersen - Pluang
Biogen Faces Legal Scrutiny After Diranersen Trial Results, Stoc - GuruFocus
Assessing Biogen (BIIB) Valuation After Recent Share Price Momentum And Earnings Expectations - simplywall.st
Biogen completes acquisition of Apellis Pharmaceuticals - Ophthalmology Times
BIIB SHAREHOLDER INVESTIGATION: SueWallSt Investigates Biogen Inc. for Possible Securities Law Violations - PR Newswire
Wedbush Maintains Biogen(BIIB.US) With Hold Rating, Maintains Target Price $196 - Moomoo
Biogen Inc Azioni (BIIB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.19%
2.96%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):